Evidence map›Paper›PMID 41614134›Full record

ArticleFrontiers in microbiology2025

Unmasking Methicillin-resistant

Torunn Gresdal Rønning, Hege Enger, Kyriakos Zaragkoulias, Christina Gabrielsen Ås

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Torunn Gresdal RønningDepartment of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Hege EngerDepartment of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Kyriakos ZaragkouliasDepartment of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Christina Gabrielsen ÅsDepartment of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Aim: This study presents the first nationwide analysis of MRSArg in Norway, detected among MRSA 18,152 isolates submitted to the Norwegian MRSA Reference Laboratory between 2008 and 2019. Methods: Clinical and epidemiological data were retrieved from national surveillance systems and laboratory records, enabling classification into healthcare- and community-associated categories. A representative panel of MRSArg genotypes ( Results: A total of 160 Conclusion: MRSArg is an emerging pathogen in Norway with both community and healthcare relevance. Improved molecular diagnostics are essential for accurate detection and surveillance.

Indexed as

diagnosticsepidemiologygenomicsmethicillin-resistanceMRSArgscreeningStaphylococcus argenteussurveillance

Identifiers

PMID41614134
PMCPMC12847390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.